Research Biosimilars – All Products

ichorbio supplies a small but growing range of biosimilars for research use only (not for diagnostic or therapeutic use).

A-Z of our biosimilars based on target:

CD20 Inhibitors

CD38 Inhibitors

CD52 Inhibitors


Complement Protein C5 Inhibitors

CTLA-4 Inhibitors

DR5 Inhibitors

EGFR Inhibitors

ErbB2 Inhibitors

IgE Inhibitors

IL-12 / IL-23 Inhibitors

IL-17A Inhibitors

IL-2R Inhibitors

IL-6 Receptor Inhibitors

Integrin a4b7 Inhibitors

PCSK9 Inhibitors

PD-1 Inhibitors

ichorbio has developed research grade versions of both nivolumab and pembrolizumab. Cemiplimab is the other FDA approved inhibitor of PD-1 and is in our product pipeline.

PD-L1 Inhibitors

ichorbio has created research use versions of atezolizumab, avelumab. Durvalumab is the other FDA approved inhibitor of PD-L1.


RANKL inhibitors


TNF alpha inhibitors

There are currently three anti-TNF antibodies that have been approved to inhibit TNF alpha: infliximab, adalimumab and golimumab. ichorbio has developed two versions of adalimumab – a standard biosimilar and a Fc-silenced version. We’ve also developed a research grade infliximab biosimilar.

VEGF Inhibitors

ichorbio has developed two VEGF inhibitors – Aflibercept and Bevacizumab. Our Bevacizumab biosimilar is also available in an Fc-silenced version.

VEGFR2 Inhibitors

ichorbio is releasing new research grade biosimilars on a weekly basis. If you have any specific requests for new products please contact us at or LiveChat.